NeurogesX 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 9, 2012 (February 9, 2012)
Date of Report (date of earliest event reported)
(Exact name of Registrant as specified in its charter)
2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404
(Address of principal executive offices)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On February 9, 2012, NeurogesX, Inc. issued a press release entitled NeurogesX Provides Update on Qutenza® (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review.
A copy of the press release, dated February 9, 2012, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The contents of the press release are deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended.
The following exhibit is filed as part of this Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.